Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Cancers · 09.01.2023 · 15 (2) · 429
DOI: 10.3390/cancers15020429 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.01.2023. Verfasst von Shigeto Nishikawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Hematology & Oncology, Children's Mercy Research Institute, Kansas City, MO 64108, USA. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
Mutations in the tumor suppressor p53 (p53) promote cancer progression. This is mainly due to loss of function (LOS) as a tumor suppressor, dominant-negative (DN) activities of missense mutant p53 (mutp53) over wild-type p53 (wtp53), and wtp53-independent oncogenic activities of missense mutp53 by interacting with other tumor suppressors or oncogenes (gain of function: GOF). Since p53 mutations occur in ~50% of human cancers and rarely occur in normal tissues, p53 mutations are cancer-specific and ideal therapeutic targets. Approaches to target p53 mutations include (1) restoration or stabilization of wtp53 conformation from missense mutp53, (2) rescue of p53 nonsense mutations, (3) depletion or degradation of mutp53 proteins, and (4) induction of p53 synthetic lethality or targeting of vulnerabilities imposed by p53 mutations (enhanced YAP/TAZ activities) or deletions (hyperactivated retrotransposons). This review article focuses on clinically available FDA-approved drugs and drugs in clinical trials that target p53 mutations and summarizes their mechanisms of action and activities to suppress cancer progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Hematology & Oncology, Children's Mercy Research Institute, Kansas City, MO 64108, USA.
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- NIH
- Braden’s Hope For Childhood Cancer
- Masonic Cancer Alliance
Zitieren
APA
Nishikawa, S., & Iwakuma, T. (2023). Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers, 15(2), 429. https://doi.org/10.3390/cancers15020429
Vancouver
Nishikawa S, Iwakuma T. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers. 2023;15(2):429. doi:10.3390/cancers15020429
BibTeX
@article{Nishikawa2023,
author = {Nishikawa, Shigeto and Iwakuma, Tomoo},
title = {Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials},
journal = {Cancers},
year = {2023},
volume = {15},
number = {2},
pages = {429},
doi = {10.3390/cancers15020429}
}
EUVIMED